SLU-PP-332 is sold as “exercise in a bottle”, and we see a lot of searches for its side effects, dosage and benefits. This guide sets out what published research actually shows, which is almost entirely animal and laboratory work, and what that means for anyone thinking about it.
SLU-PP-332 in 60 seconds
- It is a synthetic small molecule, not a peptide, designed to switch on a family of cell receptors involved in energy use and exercise.
- In mice it increased endurance, raised energy burning and reduced fat gain. In a mouse model of heart failure it was reported to help the heart.
- We could not find a published human clinical trial. How it behaves in people, and how safe it is, is not known.
- The sports anti-doping agency is reported to prohibit exercise mimetics, so athletes should treat it as off limits.
What SLU-PP-332 is
SLU-PP-332 was developed by a US research group as an agonist of the estrogen-related receptors ERR alpha, beta and gamma. These are nuclear receptors that help cells burn fuel and build energy-making machinery in muscle. The idea is an “exercise mimetic”: a drug that triggers some of the same genetic programme that exercise does. It is a small chemical, not a chain of amino acids, so it is not a peptide in the strict sense, even though it is often sold alongside them.
What the mouse studies found
- Exercise capacity. In the 2023 paper that introduced it, SLU-PP-332 increased cellular respiration in a muscle cell line and, in mice, increased the proportion of oxidative type IIa muscle fibres and improved exercise endurance. The effect depended on ERR alpha.
- Obesity and blood sugar. In a 2024 study in diet-induced obese and genetically obese mice, it raised energy expenditure and fatty acid oxidation, reduced fat mass gain and improved insulin sensitivity.
- Heart failure. A 2024 Circulation paper reported that related ERR agonists, including SLU-PP-332, improved outcomes in a mouse model of heart failure by supporting cardiac fatty acid metabolism and mitochondrial function.
Two cautions. First, every one of those results is in mice. Many compounds that work in mice never work in people. Second, several of the authors are stockholders in a company developing ERR-based drugs, which does not invalidate the work but is worth knowing.
What about humans?
A search of the PubMed database on 16 November 2026 for SLU-PP-332 together with terms for clinical trials, randomised studies, healthy volunteers or phase 1 found nothing. The closest human-related paper is a 2025 laboratory study that treated muscle cells grown from inactive women with SLU-PP-332. It found changes in genes linked to muscle health and less oxidative stress in the cells, and the authors said further studies were needed. That is cells in a dish, not people taking it. So there is no published information on dose, safety or effect in humans, and any dose you see online is a guess.
Side effects
Because there are no human trials, the side effects in people are unknown. That is different from “none reported”. It also means nobody can say how it interacts with medicines, what long-term use does, or who should avoid it. Anyone who tells you it is safe has no published human data to say so.
Sport and anti-doping
A 2026 analytical paper on detecting SLU-PP-332 states that the World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators, and describes how its metabolites could be used in doping control. If you compete in tested sport, assume it is banned and check the current prohibited list yourself.
What to ask a supplier
- Who manufactured it and in what form (capsule, pen or vial)?
- Is there a certificate of analysis for your batch, naming the product and laboratory? See how to read one.
- Can they tell you the strength per capsule or per millilitre, so you can compare price per milligram?
- Do they make any claim about benefits or dosing? Without human data, treat it as a red flag.
Where this leaves you
SLU-PP-332 is an interesting laboratory compound with promising mouse data and no published human trials. That is a reason for curiosity, not for confidence. Our products are supplied for research use only and are not registered medicines. For how other compounds compare, see our guide to the fat-loss peptides that are not GLP-1s.
Questions people ask
What is SLU-PP-332?
A synthetic small molecule that activates the estrogen-related receptors ERR alpha, beta and gamma. It was designed as an "exercise mimetic" and has been studied in mice.
Is SLU-PP-332 a peptide?
No. It is a small chemical, not a chain of amino acids, although it is often sold alongside peptides.
Does SLU-PP-332 work in humans?
Unknown. We could not find a published human clinical trial. The evidence is from mice and from cells grown in the laboratory.
What are the side effects of SLU-PP-332?
They are unknown in people, because there are no published human trials. That is not the same as no side effects.
What is the dosage of SLU-PP-332?
No human dose has been established. Any dose quoted online is not based on published human data.
Is SLU-PP-332 allowed in sport?
A 2026 paper states that the World Anti-Doping Agency prohibits exercise mimetics and metabolic modulators. Check the current prohibited list before using any such compound in tested sport.
Sources
- Billon C, et al. Synthetic ERRalpha/beta/gamma agonist induces an ERRalpha-dependent acute aerobic exercise response and enhances exercise capacity. ACS Chem Biol 2023;18:756-771.
- Billon C, et al. A synthetic ERR agonist alleviates metabolic syndrome. J Pharmacol Exp Ther 2024;388:232-240.
- Xu W, Billon C, et al. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function. Circulation 2024;149:227-250.
- Bonanni R, et al. Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study. Front Physiol 2025;16:1616693.
- Avliyakulov NK, Sobolevsky T, et al. Analysis and identification of in vitro metabolites of exercise mimetic SLU-PP-332 ERRalpha/beta/gamma agonist for doping-control purposes. Drug Test Anal 2026;18:439-450.
This article is for educational purposes only and is not medical advice. The compounds we supply are sold for research use only and are not registered medicines. Our guide to whether peptides are legal in South Africa explains what that means. Sources were checked on 16 November 2026, and new studies may have appeared since.
Compare other compounds in fat-loss peptides beyond GLP-1, or see peptides for muscle growth.

